Follow
Jonathan Cebon
Jonathan Cebon
Olivia Newton-John Cancer Research Institute
Verified email at onjcri.org.au - Homepage
Title
Cited by
Cited by
Year
Overall survival with combined nivolumab and ipilimumab in advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ...
New England Journal of Medicine 377 (14), 1345-1356, 2017
34922017
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
KT Flaherty, JR Infante, A Daud, R Gonzalez, RF Kefford, J Sosman, ...
New England Journal of Medicine 367 (18), 1694-1703, 2012
30742012
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
MR Middleton, JJ Grob, N Aaronson, G Fierlbeck, W Tilgen, S Seiter, ...
Journal of Clinical Oncology 18 (1), 158-158, 2000
16532000
Whole-genome landscapes of major melanoma subtypes
NK Hayward, JS Wilmott, N Waddell, PA Johansson, MA Field, K Nones, ...
Nature 545 (7653), 175-180, 2017
12472017
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ...
Cell 170 (6), 1109-1119. e10, 2017
12342017
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.
E Stanley, GJ Lieschke, D Grail, D Metcalf, G Hodgson, JA Gall, ...
Proceedings of the National Academy of Sciences 91 (12), 5592-5596, 1994
10801994
Type I IFNs enhance the terminal differentiation of dendritic cells
T Luft, KC Pang, E Thomas, P Hertzog, DNJ Hart, J Trapani, J Cebon
The Journal of Immunology 161 (4), 1947-1953, 1998
8021998
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
ML Burr, CE Sparbier, YC Chan, JC Williamson, K Woods, PA Beavis, ...
Nature 549 (7670), 101-105, 2017
7282017
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
ID Davis, W Chen, H Jackson, P Parente, M Shackleton, W Hopkins, ...
Proceedings of the National Academy of Sciences 101 (29), 10697-10702, 2004
5382004
Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets
T Luft, M Jefford, P Luetjens, T Toy, H Hochrein, KA Masterman, ...
Blood, The Journal of the American Society of Hematology 100 (4), 1362-1372, 2002
4792002
Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib
GV Long, JS Weber, JR Infante, KB Kim, A Daud, R Gonzalez, JA Sosman, ...
J Clin Oncol 34 (8), 871-878, 2016
3272016
Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells
M Rigau, S Ostrouska, TS Fulford, DN Johnson, K Woods, Z Ruan, ...
Science 367 (6478), eaay5516, 2020
3212020
Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial
DW Maher, GJ Lieschke, M Green, J Bishop, R Stuart-Harris, M Wolf, ...
Annals of Internal medicine 121 (7), 492-501, 1994
3131994
Tumor antigen expression in melanoma varies according to antigen and stage
C Barrow, J Browning, D MacGregor, ID Davis, S Sturrock, AA Jungbluth, ...
Clinical Cancer Research 12 (3), 764-771, 2006
3002006
Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway
M Schnurr, T Toy, A Shin, M Wagner, J Cebon, E Maraskovsky
Blood 105 (4), 1582-1589, 2005
2852005
Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies
Y Wang, KJ Han, XW Pang, HA Vaughan, W Qu, XY Dong, JR Peng, ...
The Journal of Immunology 169 (2), 1102-1109, 2002
2822002
Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma
M Sznol, PF Ferrucci, D Hogg, MB Atkins, P Wolter, M Guidoboni, ...
J Clin Oncol 35 (34), 3815-3822, 2017
2812017
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
GV Long, V Atkinson, JS Cebon, MB Jameson, BM Fitzharris, CM McNeil, ...
The Lancet Oncology 18 (9), 1202-1210, 2017
2742017
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive …
RL Basser, JEJ Rasko, K Clarke, J Cebon, MD Green, AP Grigg, ...
Blood, The Journal of the American Society of Hematology 89 (9), 3118-3128, 1997
2591997
Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer
RL Basser, JEJ Rasko, K Clarke, J Cebon, MD Green, S Hussein, C Alt, ...
The Lancet 348 (9037), 1279-1281, 1996
2551996
The system can't perform the operation now. Try again later.
Articles 1–20